Stay updated with breaking news from Aim Leukemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LEXINGTON, Mass., April 5, 2024 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April...
LEXINGTON, Mass., April 4, 2024 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James...
The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.
Eytan M. Stein, MD, discusses the ongoing development and investigation of therapies targeting splicing mutations in hematologic malignancies.
LEXINGTON, Mass., Oct. 26, 2023 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment...